Key Points
- CEO insider sale: Axon CEO Patrick Smith sold 10,000 shares for approximately $5.09 million at an average price of $508.99 under a pre-arranged Rule 10b5-1 plan. He retained 3.12 million shares following the transaction.
- Strong quarterly performance: Axon reported $1.88 in quarterly EPS and $904.39 million in revenue, exceeding analyst expectations, while revenue increased 35.3% year over year.
- Bullish outlook but elevated valuation: Analysts maintain a “Moderate Buy” consensus with an average price target of $721.57, although Axon’s high valuation— including a P/E ratio near 199—leaves the stock vulnerable to multiple compression.
Axon Enterprise, Inc (NASDAQ:AXON - Get Free Report) CEO Patrick Smith sold 10,000 shares of the firm's stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $508.99, for a total transaction of $5,089,900.00. Following the transaction, the chief executive officer directly owned 3,118,012 shares in the company, valued at $1,587,036,927.88. The trade was a 0.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Axon Enterprise Stock Down 2.3%
Axon Enterprise stock opened at $478.85 on Friday. Axon Enterprise, Inc has a fifty-two week low of $339.01 and a fifty-two week high of $792.16. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.80 and a current ratio of 2.15. The firm's 50-day simple moving average is $564.03 and its 200 day simple moving average is $488.42. The stock has a market cap of $38.90 billion, a PE ratio of 198.69, a price-to-earnings-growth ratio of 9.56 and a beta of 1.40.
Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its earnings results on Tuesday, August 4th. The biotechnology company reported $1.88 earnings per share for the quarter, topping analysts' consensus estimates of $1.84 by $0.04. The firm had revenue of $904.39 million for the quarter, compared to the consensus estimate of $876.42 million. Axon Enterprise had a return on equity of 2.84% and a net margin of 6.19%.The company's revenue was up 35.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.12 EPS. Research analysts predict that Axon Enterprise, Inc will post 2.04 EPS for the current fiscal year.
Hedge Funds Weigh In On Axon Enterprise
Institutional investors have recently bought and sold shares of the company. Evergreen Capital Management LLC increased its position in shares of Axon Enterprise by 3.8% during the second quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company's stock worth $342,000 after purchasing an additional 15 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in Axon Enterprise by 1.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 1,631 shares of the biotechnology company's stock valued at $1,350,000 after purchasing an additional 19 shares in the last quarter. Synergy Financial Group LTD lifted its holdings in Axon Enterprise by 1.4% in the 3rd quarter. Synergy Financial Group LTD now owns 1,388 shares of the biotechnology company's stock valued at $996,000 after purchasing an additional 19 shares in the last quarter. Pure Financial Advisors LLC boosted its stake in Axon Enterprise by 6.7% during the 4th quarter. Pure Financial Advisors LLC now owns 364 shares of the biotechnology company's stock worth $207,000 after purchasing an additional 23 shares during the last quarter. Finally, Van ECK Associates Corp boosted its stake in Axon Enterprise by 30.1% during the 4th quarter. Van ECK Associates Corp now owns 108 shares of the biotechnology company's stock worth $61,000 after purchasing an additional 25 shares during the last quarter. Hedge funds and other institutional investors own 79.08% of the company's stock.
Analysts Set New Price Targets
Several research analysts have weighed in on AXON shares. Morgan Stanley boosted their price objective on Axon Enterprise from $600.00 to $640.00 and gave the stock an "overweight" rating in a research report on Thursday, August 6th. Barclays raised their target price on Axon Enterprise from $523.00 to $688.00 and gave the company an "overweight" rating in a research report on Thursday, August 6th. Citizens Jmp reiterated a "market outperform" rating and set a $700.00 target price on shares of Axon Enterprise in a research note on Thursday, June 25th. Argus boosted their price target on shares of Axon Enterprise from $460.00 to $600.00 and gave the stock a "buy" rating in a report on Thursday, September 3rd. Finally, Zacks Research lowered shares of Axon Enterprise from a "strong-buy" rating to a "hold" rating in a research report on Friday, July 10th. Fourteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $721.57.
View Our Latest Stock Analysis on AXON
Key Headlines Impacting Axon Enterprise
Here are the key news stories impacting Axon Enterprise this week:
- Positive Sentiment: Analyst remains bullish: TD Cowen reaffirmed Axon as a top pick with a Buy rating and an $825 price target, citing an expected shift by cities toward Axon’s automated license-plate-recognition contracts. TD Cowen Axon analyst rating
- Positive Sentiment: Large Baltimore contract: Baltimore Police is adding 200 Axon license-plate cameras as part of a broader $153 million deal, supporting the company’s public-safety technology backlog and recurring-revenue opportunity. Baltimore Police Axon contract
- Neutral Sentiment: Technical and market factors: Analysts attributed the weakness primarily to profit-taking and broader risk-off trading in premium-valued growth stocks, rather than a new operational setback. A technical analysis identified the roughly $505 area as an important support level. Analysis of Axon share decline
- Negative Sentiment: Valuation concerns: A research report argued that rising sales and strong net revenue retention may not be sufficient to justify Axon’s elevated share price. The stock’s high earnings multiple leaves it vulnerable to additional multiple compression if growth expectations moderate. Axon earnings and valuation report
- Negative Sentiment: Insider selling adds pressure: CEO Patrick Smith sold 10,000 shares worth approximately $5.1 million under a pre-arranged Rule 10b5-1 plan. The planned nature of the transaction reduces its significance, but repeated insider sales and no reported insider purchases can weigh on sentiment. Axon CEO SEC filing
Axon Enterprise Company Profile
(
Get Free Report)
Axon Enterprise, Inc develops technology and equipment for law enforcement, public safety and other government agencies. Its product portfolio includes TASER energy weapons, body-worn cameras, in-car cameras and related connected devices designed to support safer interactions, improve transparency and collect operational data.
The company also provides cloud-based software for managing digital evidence, conducting investigations, overseeing records and workflows, coordinating dispatch and supporting real-time public safety operations.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
